Mandate

Vinge advises EQT Infrastructure II in connection with its divestment of the Hector Rail group to Ancala Infrastructure

Vinge has advised EQT Infrastructure II in connection with entering into an agreement to divest the Hector Rail group to Ancala’s European Infrastructure Fund II.

Hector Rail was acquired by EQT Infrastructure II in November 2014 and is the largest private rail freight operator in Scandinavia with significant operations in Germany. With a fleet of over 100 locomotives and 400 employees, including approximately 250 train drivers, Hector Rail transports essential goods for a wide range of customers. Hector Rail also operates a growing domestic platform in Germany, the largest rail freight market in Europe, from which it focuses on attractive niche segments, such as energy and intermodal flows.

Vinge´s team consisted of Daniel Rosvall, Karl Klackenberg, Milad Kamali and Olivia Belding (M&A), Mikael Ståhl and Axel Jansson (Banking and Finance), Mathilda Persson (Commercial Agreements) and Kristoffer Sällfors (Regulatory).

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025